BioPharma Dive

Electra nabs $183M for its rare disease drug ambitions

The San Francisco-area biotech has a therapy in mid-stage testing for secondary hemophagocytic lymphohistiocytosis, a rare ...

Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions

NASP data highlight reduction in disease burden among people living with uncontrolled goutGamifant (emapalumab) data showed response rates in ...

Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication ...
Fierce Biotech

'Some encouraging signs in the market': Electra shines with $183M fundraise for rare disease trial

Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the ...
Morningstar

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

Oral presentation at ASGCT Annual Meeting to describe algorithm to monitor, detect and treat HLH, which can be adopted for AAV gene therapy Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company ...

Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need Electra has initiated ...
Business Wire

Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and ...
Monthly Prescribing Reference

Emapalumab Gets Priority Review for HLH/MAS in Still Disease

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for emapalumab-Izsg for use in adult and ...
Medscape

Emapalumab Effective in Rheumatologic Disease–Associated Hemophagocytic Lymphohistiocytosis

Emapalumab (Gamifant)-containing regimens stabilize key laboratory parameters and show a high 12-month survival probability in patients with rheumatologic disease–associated hemophagocytic ...